Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
|
| gptkbp:activities |
alpha-2 adrenergic agonist
|
| gptkbp:brand |
gptkb:Catapres
Kapvay |
| gptkbp:category |
gptkb:C
|
| gptkbp:class |
antihypertensive
central alpha agonist |
| gptkbp:clinical_trial |
pain management
treatment of hypertension management of ADHD sedation in intensive care |
| gptkbp:contraindication |
concurrent use of MAO inhibitors
severe coronary insufficiency |
| gptkbp:dosage_form |
0.1 mg to 0.3 mg daily
|
| gptkbp:duration |
8-12 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:spacecraft
tablets |
| gptkbp:healthcare |
gptkb:1974
|
| https://www.w3.org/2000/01/rdf-schema#label |
Clonidine
|
| gptkbp:ingredients |
C9 H9 Cl2 N2
|
| gptkbp:interacts_with |
CNS depressants
beta-blockers tricyclic antidepressants |
| gptkbp:is_atype_of |
C02 A C01
|
| gptkbp:is_used_for |
hypertension
anxiety disorders ADHD opioid withdrawal |
| gptkbp:lifespan |
12-16 hours
|
| gptkbp:manager |
oral
transdermal |
| gptkbp:metabolism |
liver
|
| gptkbp:premiered_on |
1-2 hours
|
| gptkbp:side_effect |
drowsiness
constipation dry mouth hypotension bradycardia |
| gptkbp:symptoms |
anxiety
headache tremors rebound hypertension |
| gptkbp:type_of |
420-04-2
|